A Limited Sampling Method for the Estimation of Serum Calcitriol Area under the Curve in Cancer Patients

Pharmacokinetic (PK) data from 34 cancer patients receiving 2 to 10 μg of calcitriol subcutaneously (SC) were used to develop a limited sampling method for predicting serum calcitriol area under curve (AUC) based on three samples instead of the full complement of 12 to 16 samples. Serum calcitriol levels were measured by 1, 25‐dihydroxyvitamin D3‐[I125] radioimmunoassay. Individual patient‐corrected serum calcitriol AUC0–12 h was calculated by the trapezoidal rule after subtracting the pretreatment serum calcitriol level. PK data were split into “training” and “evaluation” sets based on calcitriol dose and chronological order of enrollment. Linear regression models of log‐corrected AUC0–12 h versus individual log calcitriol serum levels in the hour 1, 2, 3, 4, 6, and 8 samples were established using the training data set of 17 patients. The fit was tested on the evaluation data set of 17 patients using mean squared error (MSE) as the fit criterion. The best single time point predictor of log AUC0–12 h was the log serum (calcitriol) at hour 6 (MSE = 0.0061). The best prediction of log AUC0–12 h using two time points was found to involve hour 6 and hour 2 (MSE = 0.0018). The prediction equation for the latter model was as follows: Log AUC = 1.125 + 0.3756 • log (calcitriol) at hour 2 + 0.5859 • log (calcitriol) at hour 6. This limited sampling method was further evaluated in 83 cancer patients treated with 4 to 38 μg of oral (PO) calcitriol; observed and predicted calcitriol AUC0–12 h were highly correlated (r ≥ 0.90, p = 0.0001). These results show that serum calcitriol AUC0–12 h after SC and PO calcitriol administration is accurately estimated using pretreatment and 2‐ and 6‐hour blood samples.

[1]  P. Hershberger,et al.  Pharmacokinetics of high‐dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel , 2002, Clinical pharmacology and therapeutics.

[2]  M. Garzotto,et al.  Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. , 2001, Seminars in oncology.

[3]  D. Smith,et al.  A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  D. Smith,et al.  Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. , 1998, Journal of the National Cancer Institute.

[5]  Wei-dong Yu,et al.  Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. , 1997, Cancer research.

[6]  S. Yamada,et al.  Fluorimetric assay of 1α,25-dihydroxyvitamin D3 in human plasma , 1997 .

[7]  B. Hollis 1,25-Dihydroxyvitamin D3-26,23-lactone interferes in determination of 1,25-dihydroxyvitamin D by RIA after immunoextraction. , 1995, Clinical chemistry.

[8]  T. Stamey,et al.  Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.

[9]  D. Peehl,et al.  Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.

[10]  H. Cross,et al.  Growth control of human colon cancer cells by vitamin D and calcium in vitro. , 1992, Journal of the National Cancer Institute.

[11]  T. Aso,et al.  Fluorometric assay of 25-hydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3 in plasma. , 1992, Analytical biochemistry.

[12]  D. Feldman,et al.  1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. , 1981, Endocrinology.

[13]  Ronald D. Snee,et al.  Validation of Regression Models: Methods and Examples , 1977 .

[14]  M. Devonec,et al.  1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). , 1986, Journal of steroid biochemistry.

[15]  R. Tallarida,et al.  Manual of Pharmacologic Calculations , 1981 .